Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Flavio Ribichini, entitled “TAVI intermediate risk: Reality or passion?”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | Prevention of valvular thrombosis: antiaggregation or anticoagulation?
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Fernando Pineda, entitled “Prevention of valvular thrombosis: antiaggregation or anticoagulation?”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | TAVI: Clinical Evidence of long term durability of prosthetic valves
Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dra. Carla Agatiello, entitled “TAVI: Clinical Evidence of long term durability of prosthetic valves”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | Clinical evidence of TAVR in intermediate risk patients: Lessons from clinical trials
Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Andreas Baumbach, entitled “Clinical evidence of TAVR in intermediate risk patients: Lessons from clinical trials”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI | TAVI: Evidencia para pacientes de riesgo intermedio
Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Oscar Méndiz, entitled “TAVI: Evidencia para pacientes de riesgo intermedio”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | Role of embolic protection during Transcatheter Aortic valve replacement
Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Samir Kapadia, entitled “Role of embolic protection during Transcatheter Aortic valve replacement”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | When and how to interving patients with CAD undergoing TAVI
Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Fabio Sandoli, entitled “When and how to interving patients with CAD undergoing TAVI”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
SOLACI CACI 2017 | Role of general anesthesia compare to conscious sedation during TAVR
Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. Check the presentation of Dr. Andreas Baumbach, entitled “Role of general anesthesia compare to conscious sedation during TAVR”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Dual Antiplatelet in TAVR: Is Single Better?
Courtesy of Dr. Agustín Vecchia. As TAVR is expanded to lower risk patients, complications become more relevant. As regards stroke, the PARTNER 2 and SURTAVI one year outcomes are 8.0% and 8.2% respectively. The mechanisms behind this complication have not yet been clarified and, therefore, neither have guideline recommendations in this regard (as we can tell…
Lotus vs Sapien 3, different mechanisms with similar results
The new generation devices for transfemoral transcatheter aortic valve replacement have been optimized to improve valve position and reduce residual aortic regurgitation. This study compared 30 day, 12 month and 24 month outcomes of the repositionable, Lotus valve, with controlled mechanical expansion, and the balloon-expandable valve Edwards Sapien 3. Primary end point was all cause mortality…
How can we classify aortic stenosis in patients who underwent TAVR?
Courtesy of Dr. Carlos Fava. Aortic stenosis can present different hemodynamic patterns, such as low flow and low gradient with reduced or preserved ventricular function. However, evidence on the evolution of different hemodynamic patterns after transcatheter aortic valve replacement (TAVR) is limited. This study consisted in a retrospective analysis of 368 patients who underwent TAVR. The population was divided in…